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Rev-erbα, a component of the circadian clock, has also been known as a 
nuclear receptor that lacks activation function domain 2, functioning as a 
ligand-dependent transcriptional repressor. However, we recently reported that 
Rev-erbα activates connexin43 transcription by forming a complex with Sp1. Here we 
show that heme, a REV-ERB ligand, is dispensable for this novel mechanism and that 
Rev-erbβ, having homologies with Rev-erbα, does not activate connexin43, but 
competes with the Rev-erbα/Sp1. The A/B region of Rev-erbα, which is not conserved 
in Rev-erbβ, is a crucial activating domain, while the ligand binding domain, conserved 
in Rev-erbβ, functions as a competitor. 
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Rev-erbα and Rev-erbβ, initially identified as orphan nuclear receptors Nr1d1 
and Nr1d2, are also components of the circadian clock, have important roles in 
metabolism and cellular differentiation [1-4]. The circadian clock is genetic machinery 
that generates autonomous genetic oscillations in systemic organs by coordination of 
transcriptional activators (Bmal1 and Clock) and repressors (Per1–3 and Cry1, 2) that 
regulate other genes by binding to E boxes in promoter regions [5,6]. Concurrently, 
Rev-erbα/β and Rorα/β/ has been shown to tune the amplitude and the phase of the 
circadian clock, or control transcription of other non-clock genes, by binding to RORE 
sites of target genes [1,3,7,8]. 
Nuclear receptors modulate transcriptional activity by binding to specific 
ligands such as steroid hormones, thyroid hormone, vitamin D and retinoids, and 
function either as activators or repressors by recruiting co-activators or co-repressors, 
respectively [9,10]. Rev-erbα and Rev-erbβ have been considered to be 
ligand-dependent transcriptional repressors since they lack a canonical activation 
function domain 2 (AF-2) [11,12] and their repressive effects by recruiting nuclear 
receptor co-repressor/histone deacetylase 3 depend on their ligand of heme [13-16].  
 However, in a sharp contrast to these previous notions, we have revealed that 
Rev-erbα functions as an activator for connexin43 gene (Cx43) by forming a complex 
with Sp1 in HEK293T cells and bladder smooth muscle cells [17]. Importantly, this 
effect required proximal Sp1 sites, but no RORE sequences, on the Cx43 promoter.  
Sp1 is an Sp/KLF family transcriptional factor that regulates expression of 
multiple genes with GC-rich sequences, i.e., Sp1 binding sites, on their promoter 
regions [18,19]. The Sp1-dependent transactivation of GC-rich promoter sequences is 
reported with various nuclear proteins as well as basal transcription factors [11]. 
Interaction between Sp1 and nuclear receptors are reported with RAR, RXR, ERs and 
PPAR, which possess common structures of nuclear receptor domains including an A/B 
region (AB), a DNA binding domain (DBD), a hinge region (H) and a ligand binding 
domain (LBD) [20-22].   
 Here, we investigate the detailed mechanism by which Rev-erbα and Sp1 
complex to transactivate the Cx43 promoter in comparison with Rev-erbβ, and clarify 
the roles of Rev-erbα domains for the process. 
METHODS 
Plasmid constructs. The mouse pGL-2-Cx43 promoter-reporter (pCx43 
-1686/+165-luc), constructed by Dr. S.J. Lye [23], was a kind gift from Dr. J. Yao 
(University of Yamanashi, Yamanashi, Japan). The pRL-TK (Promega, Madison, WI) 
were used as a transfection efficacy control. The Sp1 expression vector, constructed by 
Dr. Suske [24] was a kind gift from Dr. Toguchida (Frontier Medical Sciences, Kyoto 
University, Kyoto, Japan). The expression vector of Rev-erbα and Rev-erbβ was 
purchased from Open Biosystems (Huntsville, AL). Site-directed mutagenesis, deletion 
and addition of aimed sequences were performed using a mutagenesis basal kit 
(Takara) according to the manufacturer’s protocol. These mutants were all verified by 
sequencing.  
 
Promoter-reporter assay.  Reporter plasmids with various expression vectors were 
transfected into HEK293T cells in 24-well plates using Fugene6 (Roche) in DMEM 
with 10% fetal calf serum (FCS) according to the manufacturer’s protocol. pCx43-luc 
or pGL2-basic 100 ng and pTK-RL 5 ng were transfected with various amounts of 
expression vectors (total 250 ng). Plasmid dosage was kept constant by EGFP-N1 
vector. Lysates were harvested 48 hours post-transfection, and the luciferase activity 
was measured using a dual luciferase assay reagent (Promega). For the hemin treatment, 
medium was changed to various concentration of hemin in DMEM with 10% FCS at 24 
hour after the transfection and kept for 24 hour. For SR8278 (Sigma) and GSK4112 
(Sigma) treatment, 24 hours after the transfection medium was changed to DMEM with 
10% FCS containing 10M of each reagent and incubated for additional 24 hours. 
  
Immunoblotting. Preparation of whole-cell lysates from HEK293T cells, and the 
immunoblotting procedure were performed as previously described [17,25]. Briefly, 
cells were lysed in radio-immunoprecipitation assay (RIPA) buffer containing protease 
inhibitors. The protein content of the cell lysates was measured using the BioRad 
Protein Assay Kit. Cell
 
lysates were resolved by sodium dodecyl sulfate polyacrylamide 
electrophoresis and transferred to an Immobilon-P membrane (Millipore, Bedford, MA). 
The membranes were incubated with antibodies for Sp1 (Millipore, Milford MA, 
1:2000), HA (Abcam, 1:8000), DDDDK (MBL, Aichi, Japan 1:2000), Rev-erbα (Cell 
Signaling Technology [CST], Beverly, MA, 1:500), Cx43 (Sigma, St Louis, MO, 
1:1000), Bmal1 (Santa Cruz Biotechnology, Santa Cruz, CA 1:200) and GAPDH (CST, 
1:2000). The Rev-erbα antibody of CST (2124) was for 20 amino acids between 200 
and 300 from the N terminus, including the H region. After incubation with 
HRP-conjugated anti-rabbit or anti-mouse secondary antibodies (Pierce, Rockford, IL), 
immunoreactive proteins were visualized using a Super Signal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL). 
 
Co-immunoprecipitation assay. Preparation of nuclear extracts and 
co-immunoprecipitation were performed as previously described [17]. Briefly nuclear 
extracts were prepared from HEK293T cells in 10 cm dishes, transfected with 
HA-Rev-erbα or HA-Rev AB (3.75 g), and DDDDK-Sp1 (3.75 g) expression vectors 
for 48 hours, using Nuclear Complex Co-IP kit (Active Motif, Carlsbad, CA). The 100 
µg of nuclear extracts were incubated with 4 µg of antibodies for HA and control rabbit 
IgG (Zymed) in 500 µl of low IP buffer overnight at 4 °C with rotation followed by 
addition of 30 µl of Dynabeads Sheep anti-Rabbit IgG (Veritas, Tokyo, Japan) for 1 
hour. After washing with low IP buffer, the binding protein was eluted in 40 µl of RIPA 
buffer for immunoblotting. The 2 µg of nuclear extracts were used as input. 
 
Statistical analysis. We used one-way ANOVA followed by Tukey’s post-hoc test for 
the multiple comparisons or by Dunnett’s post-hoc test for comparing to the control in 
the promoter-reporter assay, calculated with SPSS ver.11.0.1J software (SPSS Inc., 
Chicago, IL). A P value < 0.05 was accepted as significant. 
 
RESULTS AND DISCUSSION 
Ligand is dispensable for activation by Rev-erbα with Sp1 
Firstly, to investigate whether the transactivation of Cx43 promoter by 
Rev-erbα/Sp1 complex is controlled by heme, the ligand of Rev-erbα as a nuclear 
receptor, we applied various concentrations of heme to the HEK293T cells transfected 
with Rev-erbα/Sp1. Exogenously applied heme showed little impact on the Cx43 
promoter activation (Fig. 1A), while it enhanced the suppressive effect on the 
abundance of Bmal1 protein as reported (Fig. 1B) [13,15]. In addition, SR8278, an 
antagonist of REV-ERB, was applied to block the action of endogenous agonist heme, 
which is always present in the cells [26]. It also had little effect on the Cx43 promoter 
activation, which was not influenced by addition of GSK4112, an agonist of REV-ERB 
(Supplementary Fig. S1). Notably, although the ligand binding domain (LBD) of 
Rev-erbα has been reported to be crucial for recruiting co-repressors [14,15], a deletion 
mutant of LBD of Rev-erbα (Rev ΔLBD) still retained transactivation activity for the 
Cx43 promoter (Fig. 1C). In contrast to the suppressive effect of Rev-erbα, the ligand is 
not considered to play a significant role in the transactivation mechanism.  
 
Rev-erbβ competes with Rev-erbα and Sp1 complex 
Next, to investigate whether Rev-erbβ transactivates the Cx43 promoter in a 
similar manner as Rev-erbα with Sp1, we drove expression of Rev-erbβ in conjunction 
with a Cx43 promoter-reporter. However, Rev-erbβ scarcely affected the promoter 
activity of Cx43 even when co-expressed with Sp1 (Fig. 2A). Intriguingly, Rev-erbβ 
competed with Rev-erbα in the presence of Sp1 for the transactivation of the Cx43 
promoter (Fig. 2B). This result is completely different from the previous notion that 
Rev-erbα and Rev-erbβ have nearly identical functions in the liver [27]. These results 
prompted us to investigate the precise mechanism of Cx43 promoter transactivation by 
Rev-erbα with Sp1. 
 
The A/B region of Rev-erbα is an activation domain.  
Alignment comparison of Rev-erbα with Rev-erbβ disclosed that they have a 
different A/B region but a similar DNA binding domain (DBD), a hinge region (H) and 
a C terminal region of their LBD (Supplementary Fig. S2). According to their 
similarities and differences, we generated various domain oriented deletion mutants of 
Rev-erbα to examine the domains responsible for the activation of Cx43 (Fig. 3A). The 
promoter-reporter assay revealed that, a part of the N terminal region of Rev-erbα 
(8-49) and the LBD were not crucial for the activation of the Cx43 promoter, while the 
A/B region, DBD and H region were indispensable (Fig. 3B). These effects were also 
confirmed at the protein level by immunoblotting (Fig. 3C). In accordance with 
previous reports [1,14], wild-type (WT) Rev-erbα successfully suppressed Bmal1 
protein expression. Notably, in contrast to the transactivation of the Cx43 promoter, 
co-transfection of a deletion mutant of the A/B region (ΔAB) still had a suppressive 
effect on Bmal1 expression, while those with deletions of the DBD, H region or LBD 
(ΔDBD, ΔH and ΔLBD) failed to suppress it.  
In light of these results, we focused on the A/B region as an activation domain 
and generated a DNA construct for expression of this region alone (HA-Rev AB). 
Indeed, the HA-Rev AB still transactivated the Cx43 promoter transfected with Sp1 
(Fig. 3D) and the HA-Rev AB was co-immunoprecipitated with Sp1 (Fig. 3E).  
 
The LBD of Rev-erbα is a competition domain. 
Rev ΔAB, a mutant Rev-erbα without A/B region, not only failed to activate, 
but inhibited the transactivation of Cx43 promoter by Rev-erbα with Sp1 in a dose 
dependent manner (Fig. 4A), indicating that Rev ΔAB contains a competition domain 
for Rev-erbα/Sp1 complex to transactivate the Cx43 promoter.  
To identify the competition domain of Rev-erbα, we assessed the effect of Rev 
ΔH, Rev DBDLBD (a mutant of Rev-erbα only with the DBD and LBD) or Rev DBD 
(a mutant of Rev-erbα only with the DBD) with Rev-erbα/Sp1 (Supplementary Fig. 
S3). The competition was observed in Rev ΔH and Rev DBDLBD but not in Rev DBD, 
indicating that not the H region or DBD but the LBD could be the required domain. 
Indeed, Rev LBD (a mutant of Rev-erbα only with LBD) competed with the 
Rev-erbα/Sp1 (Fig. 4B). Therefore, the LBD is involved in the transactivation of the 
Cx43 promoter by Rev-erbα/Sp1 complex as a potential competition domain. 
Thus, different amino acid arrangements in the A/B activation domain regions 
of Rev-erbα and Rev-erbβ may underlie their differential activation of the Cx43 
promoter. Conversely, high compatibility in LBD between these two Rev-erb subtypes 
may underlie the competitive effect of by Rev-erbα by Rev-erbβ (Fig. 4C). We should 
note that this relationship between Rev-erbα and Rev-erbβ is similar to the relationship 
between Estrogen Receptor (ER) α and ERβ. The importance of the A/B region of 
nuclear receptors for associating with Sp1 has also been postulated for this ER family. 
Saville and coworkers reported that the ERα possesses a transactivation function, but 
ERβ does not, while a chimeric ERα/β, possessing the A/B region of ERα and other 
domains of ERβ, also has a transactivation function on a 17-beta Estradiol 2-responsive 
construct containing a GC-rich promoter [28]. ERα and ERβ are also competitive on the 
Sp1 site of the promoter [28]. Li and coworkers demonstrated that amino acids 67-139 
of ERα, a part of the A/B region, were sufficient for the transactivation by ERα/Sp1 
[29].  
The physiological implication of this novel competitive role for Rev-erbβ is 
unclear. Rev-erbβ is also a component of the circadian clock [27,30] and oscillates in 
the urinary bladder (Supplementary Fig. S4), thus one could speculate that Rev-erbβ 
tunes the circadian expression of Cx43 by competing with Rev-erbα. Because the peak 
expression of Rev-erbβ is 3.6 h later than Rev-erbα, followed by Cx43 (Supplementary 
Fig. S4) in the urinary bladder, Rev-erbβ may contribute to decrease the transactivation 
of Cx43 after the peak point. Since the present study relies to a large extent on 
overexpression and reporter assays, physiological relevance and functional significance 
of the findings still remains to be determined. 
As other limitation of the present study, we showed the specific role of 
Rev-erbα domains for transactivation of the Cx43 promoter, but not the specific amino 
acid sequence required for the activation by Rev-erbα/Sp1 complex. The molecular 
structure of the complex, including the detailed interaction with Sp1 and other 
co-activators and/or co-repressors, which may also induce differences in effect of 
Rev-erbα/β [31-34], remains to be investigated to elucidate the entire mechanism of this 
novel transcription complex.  
In summary, the present study shows that heme as the ligand is dispensable for 
transactivation of the Cx43 promoter by Rev-erbα with Sp1, and that the A/B region of 
Rev-erbα functions as an activation domain, while the LBD of Rev-erbα is a 
competition domain. This mechanism may underlie the competitive effect by Rev-erbβ 
on the transactivation. These findings provide a new insight into interaction between 
the clock regulator/nuclear receptors and Sp1.  
 
REFERENCES 
 1. Preitner N, Damiola F, Lopez Molina L, Zakany J, Duboule D, Albrecht U, 
Schibler U (2002) The orphan nuclear receptor REV-ERBalpha controls circadian 
transcription within the positive limb of the mammalian circadian oscillator. Cell. 
110; 251-260. 
 2. Etchegaray JP, Lee C, Wade PA, Reppert SM (2003) Rhythmic histone 
acetylation underlies transcription in the mammalian circadian clock. Nature. 421; 
177-182. 
 3. Burris TP (2008) Nuclear hormone receptors for heme: REV-ERBalpha and 
REV-ERBbeta are ligand-regulated components of the mammalian clock. Mol 
Endocrinol. 22; 1509-1520. 
 4. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong LW, DiTacchio L, 
Atkins AR et al (2012) Regulation of circadian behaviour and metabolism by 
REV-ERB-alpha and REV-ERB-beta. Nature. 485; 123-127. 
 5. Okamura H, Doi M, Fustin JM, Yamaguchi Y, Matsuo M (2010) Mammalian 
circadian clock system: Molecular mechanisms for pharmaceutical and medical 
sciences. Adv Drug Deliv Rev. 62; 876-884. 
 6. Ukai H, Ueda HR (2010) Systems biology of mammalian circadian clocks. Annu 
Rev Physiol. 72; 579-603. 
 7. Mirsky HP, Liu AC, Welsh DK, Kay SA, Doyle FJ 3rd (2009) A model of the 
cell-autonomous mammalian circadian clock. Proc Natl Acad Sci U S A. 106; 
11107-11112. 
 8. Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. 
Nature. 418; 935-941. 
 9. Glass CK, Saijo K (2010) Nuclear receptor transrepression pathways that regulate 
inflammation in macrophages and T cells. Nat Rev Immunol. 10; 365-376. 
10. Huang P, Chandra V, Rastinejad F (2010) Structural overview of the nuclear 
receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol. 
72; 247-272. 
11. Safe S, Kim K (2004) Nuclear receptor-mediated transactivation through 
interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol. 77; 1-36. 
12. Woo EJ, Jeong DG, Lim MY, Jun Kim S, Kim KJ, Yoon SM, Park BC, Eon Ryu 
S (2007) Structural insight into the constitutive repression function of the nuclear 
receptor Rev-erbbeta. J Mol Biol. 373; 735-744. 
13. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris 
LL, Khorasanizadeh S, Burris TP et al (2007) Identification of heme as the ligand 
for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct 
Mol Biol. 14; 1207-1213. 
14. Yin L, Lazar MA (2005) The orphan nuclear receptor Rev-erbalpha recruits the 
N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. 
Mol Endocrinol. 19; 1452-1459. 
15. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, Waitt GM, Parks 
DJ, Pearce KH et al (2007) Rev-erbalpha, a heme sensor that coordinates 
metabolic and circadian pathways. Science. 318; 1786-1789. 
16. Feng D, Liu T, Sun Z, Bugge A, Mullican SE, Alenghat T, Liu XS, Lazar MA 
(2011) A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic 
lipid metabolism. Science. 331; 1315-1319. 
17. Negoro H, Kanematsu A, Doi M, Suadicani SO, Matsuo M, Imamura M, Okinami 
T, Nishikawa N, Oura T et al (2012) Involvement of urinary bladder Connexin43 
and the circadian clock in coordination of diurnal micturition rhythm. Nat 
Commun. 3; 809. 
18. Suske G (1999) The Sp-family of transcription factors. Gene. 238; 291-300. 
19. Kaczynski J, Cook T, Urrutia R (2003) Sp1- and Kruppel-like transcription factors. 
Genome Biol. 4; 206. 
20. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, Kojima S (1999) 
Physical interaction between retinoic acid receptor and Sp1: mechanism for 
induction of urokinase by retinoic acid. Blood. 93; 4264-4276. 
21. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S (2001) 
Transactivation via RAR/RXR-Sp1 interaction: characterization of binding 
between Sp1 and GC box motif. Mol Endocrinol. 15; 1677-1692. 
22. Sun G, Porter W, Safe S (1998) Estrogen-induced retinoic acid receptor alpha 1 
gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol. 12; 
882-890. 
23. Chen ZQ, Lefebvre D, Bai XH, Reaume A, Rossant J, Lye SJ (1995) 
Identification of two regulatory elements within the promoter region of the mouse 
connexin 43 gene. J Biol Chem. 270; 3863-3868. 
24. Hagen G, Muller S, Beato M, Suske G (1994) Sp1-mediated transcriptional 
activation is repressed by Sp3. EMBO J. 13; 3843-3851. 
25. Negoro H, Kanematsu A, Imamura M, Kimura Y, Matsuoka R, Tanaka M, Tabata 
Y, Ogawa O (2011) Regulation of connexin 43 by basic fibroblast growth factor 
in the bladder: transcriptional and behavioral implications. J Urol. 185; 
2398-2404. 
26.  Kojetin D, Wang Y, Kamenecka TM, Burris TP (2011) Identification of SR8278, 
a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol 6; 
131-134 
27. Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE, Wang F, Jager J, Lazar 
MA (2012) Rev-erbalpha and Rev-erbbeta coordinately protect the circadian clock 
and normal metabolic function. Genes Dev. 26; 657-667. 
28. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, 
Safe S (2000) Ligand-, cell-, and estrogen receptor subtype 
(alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol 
Chem. 275; 5379-5387. 
29. Li C, Briggs MR, Ahlborn TE, Kraemer FB, Liu J (2001) Requirement of Sp1 and 
estrogen receptor alpha interaction in 17beta-estradiol-mediated transcriptional 
activation of the low density lipoprotein receptor gene expression. Endocrinology. 
142; 1546-1553. 
30. Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, Iino M, 
Hashimoto S (2005) System-level identification of transcriptional circuits 
underlying mammalian circadian clocks. Nat Genet. 37; 187-192. 
31. Phelan CA, Gampe RT Jr, Lambert MH, Parks DJ, Montana V, Bynum J, 
Broderick TM, Hu X, Williams SP et al (2010) Structure of Rev-erbalpha bound 
to N-CoR reveals a unique mechanism of nuclear receptor-co-repressor interaction. 
Nat Struct Mol Biol 17; 808-814. 
32. Pascal E, Tjian R (1991) Different activation domains of Sp1 govern formation of 
multimers and mediate transcriptional synergism. Genes Dev. 5; 1646-1656. 
33. Husmann M, Dragneva Y, Romahn E, Jehnichen P (2000) Nuclear receptors 
modulate the interaction of Sp1 and GC-rich DNA via ternary complex formation. 
Biochem J. 352; 763-772. 
34. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE, Zhang J (2004) Estrogen 
response element-dependent regulation of transcriptional activation of estrogen 





We thank R. Stout and E. Nakamura for valuable discussions and editing the 
manuscript, S.J. Lye and J. Yao for providing pCx43-luc, G. Suske and J. Toguchida 
for providing Sp1 expression vector. This work was supported by a Grant-in-Aid for 
Scientific Research (21390439 and 23659756) from the Japan Society for the 
Promotion of Science (JSPS). 
  
AUTHOR CONTRIBUTIONS 
H.N. and A.K designed the experiments and composed the manuscript. H.N. performed 
the experiments and analyzed data. T.O and M.I helped with the experiments. Y.T. and 
O.O. supervised the study. 
 
CONFLICT OF INTEREST    
The authors declare that they have no conflict of interest.  
 
LEGENDS 
Figure 1 Ligand independent activation by the Rev-erbα and Sp1 complex. (A) 
Addition of hemin, a ligand of Rev-erbα, did not increase the effect of Rev-erbα 
and Sp1 on Cx43 transcription. N=3 for each group. (B) Bmal1expression was 
decreased by addition of hemin on Rev-erbα and Sp1. (C) A mutant with deletion 
of the ligand binding domain (Δ287-610: Rev ΔLBD) still transactivated the Cx43 
promoter. *P < 0.0001 compared with the control without transfection of Rev-erbα 
by one-way ANOVA followed by Dunnett’s post-hoc test. +, 125 ng in A and C. 
Error bars represent s.d. in A and C. For relative levels, Rev-erbα + Sp1 + hemin 0 
μM was set to 1 in A, and the control as Rev-erbα - Sp1 - was set to 1 in C. 
 
Figure 2 Rev-erbβ competes with the Rev-erbα and Sp1 complex. (A) Rev-erbβ 
did not transactivate Cx43 promoter. *P < 0.0001 vs. Rev-erbβ -, Rev-erbα - Sp1 
- ; †P < 0.0001 vs. Rev-erbβ - Rev-erbα - Sp1 + by one-way ANOVA followed by 
Tukey’s post-hoc test. N=3 for each group. +, 125 ng; ++ 250 ng. (B) Rev-erbβ 
competes with Rev-erbα and Sp1 complex for transactivation of Cx43 promoter. 
N=3. *p<0.0005 vs. Rev-erbβ - Rev-erbα - Sp1 - or +; †p<0.0001 vs. Rev-erbβ - 
Rev-erbα + Sp1 + by one-way ANOVA followed by Tukey’s post-hoc test. +, 50 
ng; +++, 150 ng. Error bars represent s.d. in A and B. The controls without 
Rev-erbα and Sp1 were set as 1 in A and B.  
 
Figure 3 A/B region dependent activation of the Rev-erbα and Sp1 complex. (A) 
Schematic representations of deletion mutants of Rev-erbα. (B) The AB region 
(8-126), DNA binding domain (DBD, 127-203) and hinge regions (H, 204-286) are 
crucial to activate the Cx43 promoter. +, 125 ng; n=3 for each group. *P < 0.0001 
compared with Rev-erbα - Sp1 -; †P < 0.0001 compared with Rev-erbα - Sp1 + by 
one-way ANOVA followed by Tukey’s post-hoc test. (C) Validation of the protein 
expression of mutant Rev-erbα and effects on Cx43 protein expression by 
immunoblotting. The antibody for Rev-erbα (CST), made against the 20 amino 
acids between 200 and 300 from the N terminus, including the H region, did not 
recognize Rev ΔH accordingly. Bmal1 is a positive control of DBD and 
LBD-indispensable negative regulatory effect by Rev-erbα. (D) The A/B region of 
Rev-erbα transactivated the Cx43 promoter with Sp1 by itself based on the effect of 
HA-Rev AB (a mutant of Rev-erbα with A/B region only). N=3 for each. *P < 
0.0001 by one-way ANOVA followed by Tukey’s post-hoc test. (E) The A/B 
region of Rev-erbα makes a complex with Sp1. DDDDK tagged Sp1 was 
co-immunoprecipitated using an antibody for HA in HEK293T cells transfected 
with HA-Rev AB and DDDDK-Sp1. For relative levels, the control without 
Rev-erbα and Sp1 was set as 1 in B and D.      
 
Figure 4 The LBD of Rev-erbα competes with the Rev-erbα and Sp1 complex. (A) 
Deletion of the A/B region of Rev-erbα competed with the Rev-erbα and Sp1 
complex to transactivate the Cx43 promoter. N=3 for each. *P < 0.005 compared 
with Rev-erbα - Sp1 -; †P < 0.005 compared with Rev WT 1.7 Sp1 1.7 by one-way 
ANOVA followed by Tukey’s post-hoc test. 1, 37.5 ng; 1.7, 62.5 ng; 2.7, 100 ng; 
3.3, 125 ng; 5, 187.5 ng; +, 62.5 ng. (B) A mutant of Rev-erbα with only the LBD 
competes against the WT Rev-erbα as does a mutant with both the DBD and LBDs. 
N=3 for each. *P < 0.005 compared with Rev-erbα - Sp1 -; †P < 0.005 compared 
with Rev WT 1.7 Sp1 1.7 by one-way ANOVA followed by Tukey’s post-hoc test. 
Error bars represent s.d. in A and B. The controls without Rev-erbα and Sp1 were 
set as 1 in A and B. (C) A putative mechanistic scheme for the transactivation of 
the Cx43 promoter by Rev-erbα complexed with Sp1. The A/B region of Rev-erbα 
interacts with Sp1 as an activation domain and the LBD is a competitive domain. 
Rev-erbβ, possessing a relatively different A/B region and a similar C terminal 
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Supplementary Figure S1 | Minor effect of a synthetic antagonist or agonist of REV-ERB on pCx43 
activation by the Rev-erbα and Sp1 complex. Addition of SR8278, a synthetic antagonist of REV-ERB, with and 
without a synthetic agonist GSK4112, did not have major impact on the effect of Rev-erbα and Sp1 on Cx43 transcription. 
N=3 for each group. +, 125 ng. Error bars represent s.d. For relative levels, Rev-erbα + Sp1 + without SR8278 and 
























































Supplementary Figure S2 | Alignments between human REV-ERBα and REV-ERBβ. Human REV-ERB and 
REV-ERBhave a relatively different A/B region and a similar C terminal LBD analysed by CLUSTAL W. An asterisk, 
double dots and a dot indicate an identical or conserved residue, a conserved substitution and a semiconserved substitution. 





Supplementary Figure S3 
 
 
Supplementary Figure S3 | Mutants of Rev-erbα with the LBD compete against WT Rev-erbα. HA-Rev 
DBD LBD, a mutant of Rev-erbα only with the DBD and LBD; HA-Rev DBD, a mutant of Rev-erbα only with the DBD. 
N=3 for each. *P < 0.005 compared with Rev-erbα - Sp1 -; †P < 0.005 compared with Rev WT 1.7 Sp1 1.7 by one-way 
ANOVA followed by Tukey’s post-hoc test. 1, 37.5 ng; 1.7, 62.5 ng; 2.7, 100 ng; 3.3, 125 ng; 5, 187.5 ng; +, 62.5 

















































Supplementary Figure S4 | Temporal gene expressions of Rev-erbα, Rev-erbβ and Connexin43 in the 
urinary bladder in mice. The max correlation efficiency to 60 phase different cosine curves of Rev-erb, Rev-erb and 
Conneixn43 are 0.99, 0.98 and 0.86, respectively and the peak phase are CT 7.2, 10.8 and 11.6 respectively. These figures 
are based on the microarray data deposited in the Gene Expression Omnibus under accession code GSE35795 (ref.17). 
 
 
 
 
